Rezolute reports fourth quarter and full year fiscal 2021 financial results and highlights recent company progress

Redwood city, calif., sept. 15, 2021 (globe newswire) -- rezolute, inc. (nasdaq: rzlt), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the fourth quarter and fiscal full year ended june 30, 2021.
RZLT Ratings Summary
RZLT Quant Ranking